HK1160598A1 - 治療腎功能紊亂的組合物和方法 - Google Patents

治療腎功能紊亂的組合物和方法

Info

Publication number
HK1160598A1
HK1160598A1 HK12100865.8A HK12100865A HK1160598A1 HK 1160598 A1 HK1160598 A1 HK 1160598A1 HK 12100865 A HK12100865 A HK 12100865A HK 1160598 A1 HK1160598 A1 HK 1160598A1
Authority
HK
Hong Kong
Prior art keywords
compositions
treatment
methods
kidney disorders
kidney
Prior art date
Application number
HK12100865.8A
Other languages
English (en)
Inventor
凱倫．安妮特．杜甘
Original Assignee
維克特斯生物系統有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008905378A external-priority patent/AU2008905378A0/en
Application filed by 維克特斯生物系統有限公司 filed Critical 維克特斯生物系統有限公司
Publication of HK1160598A1 publication Critical patent/HK1160598A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HK12100865.8A 2008-10-17 2012-01-31 治療腎功能紊亂的組合物和方法 HK1160598A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008905378A AU2008905378A0 (en) 2008-10-17 Compositions and methods for treatment of kidney disorders
PCT/AU2009/001367 WO2010042997A1 (en) 2008-10-17 2009-10-16 Compositions and methods for treatment of kidney disorders

Publications (1)

Publication Number Publication Date
HK1160598A1 true HK1160598A1 (zh) 2012-08-10

Family

ID=42106133

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12100865.8A HK1160598A1 (zh) 2008-10-17 2012-01-31 治療腎功能紊亂的組合物和方法

Country Status (19)

Country Link
US (2) US8569235B2 (zh)
EP (1) EP2349320B1 (zh)
JP (1) JP2012505835A (zh)
KR (1) KR101671406B1 (zh)
CN (1) CN102186496A (zh)
AU (1) AU2009304595B2 (zh)
BR (1) BRPI0914504B8 (zh)
CA (1) CA2740989C (zh)
DK (1) DK2349320T3 (zh)
ES (1) ES2603963T3 (zh)
HK (1) HK1160598A1 (zh)
IL (2) IL212353A0 (zh)
MX (1) MX336384B (zh)
MY (1) MY160560A (zh)
NZ (2) NZ603602A (zh)
RU (1) RU2519124C2 (zh)
SG (1) SG10201501316VA (zh)
WO (1) WO2010042997A1 (zh)
ZA (1) ZA201103572B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620566B8 (pt) * 2005-12-09 2021-05-25 Vectus Biosystems Ltd composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CA2953975C (en) 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
EP2349320B1 (en) * 2008-10-17 2016-06-22 Vectus Biosystems Limited Compositions and methods for treatment of kidney disorders
BRPI1006748A2 (pt) * 2009-04-02 2018-03-06 Vectus Biosystems Pty Ltd método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica
ES2606140T3 (es) 2010-10-01 2017-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente
CN104130663B (zh) * 2014-06-27 2017-01-04 南安市永腾技术咨询有限公司 一种用于包装机的金属防腐漆及其制备方法
NZ736165A (en) * 2015-03-18 2022-07-01 Vectus Biosystems Ltd Compositions for the treatment of kidney and/or liver disease
US9779043B2 (en) 2015-11-16 2017-10-03 International Business Machines Corporation Techniques for handling queued interrupts in a data processing system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003253645A1 (en) 2002-06-12 2003-12-31 The Board Of Trustees Of The University Of Illinois Phospholipid micelles in liposomes as solubilizers for water-insoluble compounds
EP1571155B1 (en) * 2002-11-27 2011-08-24 Ils Inc. Peptides and medicinal compositions containing the same
JP4824682B2 (ja) * 2004-06-11 2011-11-30 ベクタス・バイオシステムズ・リミテッド 循環器病の治療のための組成物および方法
US9006181B2 (en) 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
BRPI0620566B8 (pt) * 2005-12-09 2021-05-25 Vectus Biosystems Ltd composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip
EP2349320B1 (en) * 2008-10-17 2016-06-22 Vectus Biosystems Limited Compositions and methods for treatment of kidney disorders
BRPI1006748A2 (pt) * 2009-04-02 2018-03-06 Vectus Biosystems Pty Ltd método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica

Also Published As

Publication number Publication date
US20110218149A1 (en) 2011-09-08
DK2349320T3 (en) 2016-09-26
US20140080758A1 (en) 2014-03-20
KR20110095266A (ko) 2011-08-24
AU2009304595B2 (en) 2015-02-05
CN102186496A (zh) 2011-09-14
ES2603963T3 (es) 2017-03-02
US9238054B2 (en) 2016-01-19
EP2349320A1 (en) 2011-08-03
EP2349320B1 (en) 2016-06-22
CA2740989C (en) 2016-07-12
IL235888A (en) 2017-08-31
AU2009304595A1 (en) 2010-04-22
MX2011004031A (es) 2011-06-27
JP2012505835A (ja) 2012-03-08
WO2010042997A1 (en) 2010-04-22
BRPI0914504A2 (pt) 2016-01-12
ZA201103572B (en) 2012-01-25
IL212353A0 (en) 2011-06-30
RU2011114857A (ru) 2012-11-27
KR101671406B1 (ko) 2016-11-01
US8569235B2 (en) 2013-10-29
EP2349320A4 (en) 2012-12-26
BRPI0914504B8 (pt) 2021-05-25
BRPI0914504B1 (pt) 2020-11-10
NZ592612A (en) 2013-01-25
CA2740989A1 (en) 2010-04-22
MX336384B (es) 2016-01-18
RU2519124C2 (ru) 2014-06-10
NZ603602A (en) 2013-09-27
SG10201501316VA (en) 2015-05-28
MY160560A (en) 2017-03-15

Similar Documents

Publication Publication Date Title
IL258730A (en) Preparations and methods for the treatment of microbial disorders
HK1249446A1 (zh) 用於治療乳糜瀉的組合物和方法
EP2293800A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES
EP2259679A4 (en) METHOD FOR THE TREATMENT OF CALLIQUE CLEANING DISORDERS
HK1160598A1 (zh) 治療腎功能紊亂的組合物和方法
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
IL209032A0 (en) Compositions and methods for treating digestive disorders
IL208354A0 (en) Methods of treatment
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
PL2182981T3 (pl) Sposoby i kompozycje do leczenia i diagnozowania zwłóknienia
WO2011049960A9 (en) Compositions and methods for the treatment of sinonasal disorders
HK1159498A1 (zh) 用於治療癌症的方法和組合物
SI2300614T1 (sl) Metode in sestavki za zdravljenje mitohondrijskih motenj
EP2268292A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2182810A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING OSTEOARTHRITIS
EP2271352A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE
EP2355657A4 (en) Compositions and methods for treating endothelial dysfunction
EP2249789A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSOMY
EP2285398A4 (en) METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS
EP2164494A4 (en) Methods of Treatment
EP2370087A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
AU2008905378A0 (en) Compositions and methods for treatment of kidney disorders
GB0819446D0 (en) Treatment of inflammatory disorders